Elsevier Announces a New Concept Methods Journal: MethodsX

February 3, 2014

AMSTERDAM, February 3, 2014 /PRNewswire/ –

Open Access journal MethodsX provides a home for publishing work which otherwise
remains unpublished

Elsevier [http://www.elsevier.com/_nocache ], a world-leading provider of scientific,
technical and medical information products and services, today announced a new concept
methods journal: MethodsX [http://www.elsevier.com/locate/methodsx ].

Researchers spend up to 80% of their time customizing and tweaking existing methods to
make them better fit their specific research setting. By providing a home for these often
unpublished records, MethodsX allows researchers to receive public credit and citations
for that work without spending time writing a full, traditional research article.

“This is a new approach to scientific publishing. We believe that MethodsX will
dramatically change how researchers assess and build on recognized techniques, saving the
scientific community valuable time and money,” commented Irene Kanter-Schlifke, Executive
Publisher at Elsevier.

As an online-only, open access journal, MethodsX publishes papers in all disciplines
of experimental research, from Life Sciences to Health Sciences to Physical Sciences.

A paper published in MethodsX includes:

        - an abstract to outline the customization
        - an image, graph or other visual to illustrate what's been done
        - the methodological protocol(s)

“MethodsX fulfills a real need for researchers to publish their work on developing
methods so that they can easily be found by others,” said Gregory J. Tsongalis, Advising
Editor for MethodsX and Professor of Pathology at the Dartmouth Hitchcock Medical Center
and The Audrey and Theodor Geisel School of Medicine at Dartmouth. “It’s also good for
researchers as they can get recognized for their time and effort.”

The first articles are now freely available online on ScienceDirect:


For more information or to submit an article, visit


# # #

About Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today,
researchers can choose to publish open access in over 1,600 established peer-reviewed
journals as well as 82 full open access journals and these numbers will continue to grow
rapidly. All of Elsevier’s open access publications have been peer reviewed, ensuring that
the broader community not only reads the latest research but that it is factual, original
and of the highest quality and ethical standards. For more information about Elsevier’s
open access program, visit http://www.elsevier.com/openaccess

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and 25,000 book titles,
including major reference works from Mosby and Saunders. Elsevier’s online solutions
include ScienceDirect [http://www.sciencedirect.com ], Scopus [http://www.scopus.com ],
SciVal [http://info.scival.com ], Reaxys [http://www.elsevier.com/reaxys ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, helping research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Lucy Goodchild

SOURCE Elsevier

Source: PR Newswire

comments powered by Disqus